BioNTech SE (BNTX) Insider Trading

Last 12 months

Insiders sold $89.8M and bought nothing on the open market.

All of the selling was scheduled in advance under 10b5-1 plans. No executive or director has bought shares on the open market in the last two years.

Net open-market

−$89.8M

0 buys · 15 sales

Under a 10b5-1 plan

100%

of the value sold

Insiders who bought / sold

0 / 2

executives and directors

Last open-market buy

None

in the last two years

Get an email when BNTX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 8 – 9	Ugur Sahin Chief Executive Officer	Sold10b5-1 plan 2 parts	63,209	$94.07 average	$5.95M	0.2%	Form 4
Oct 7	Ugur Sahin Chief Executive Officer	Sold10b5-1 plan	24,000	$95.86	$2.3M	<0.1%	Form 4
Oct 5 – 6	Ugur Sahin Chief Executive Officer	Sold10b5-1 plan 2 parts	93,000	$97.14 average	$9.03M	0.2%	Form 4
Oct 1 – 2	Ugur Sahin Chief Executive Officer	Sold10b5-1 plan 2 parts	34,000	$97.09 average	$3.3M	<0.1%	Form 4
Sep 29 – 30	Ugur Sahin Chief Executive Officer	Sold10b5-1 plan 2 parts	66,000	$98.19 average	$6.48M	0.2%	Form 4
Sep 25 – 28	Ugur Sahin Chief Executive Officer	Sold10b5-1 plan 2 parts	61,000	$98.57 average	$6.01M	0.2%	Form 4
Sep 23 – 24	Ugur Sahin Chief Executive Officer	Sold10b5-1 plan 2 parts	69,000	$99.17 average	$6.84M	0.2%	Form 4
Sep 21 – 22	Ugur Sahin Chief Executive Officer	Sold10b5-1 plan 2 parts	79,000	$99.50 average	$7.86M	0.2%	Form 4
Sep 17 – 18	Ugur Sahin Chief Executive Officer	Sold10b5-1 plan 2 parts	64,000	$97.48 average	$6.24M	0.2%	Form 4
Sep 15 – 16	Ugur Sahin Chief Executive Officer	Sold10b5-1 plan 2 parts	49,000	$96.37 average	$4.72M	0.1%	Form 4
Sep 11 – 14	Ugur Sahin Chief Executive Officer	Sold10b5-1 plan 2 parts	86,000	$98.13 average	$8.44M	0.2%	Form 4
Sep 10	Ugur Sahin Chief Executive Officer	Sold10b5-1 plan	20,500	$96.31	$1.97M	<0.1%	Form 4
Sep 8 – 9	Ugur Sahin Chief Executive Officer	Sold10b5-1 plan 2 parts	73,000	$98.50 average	$7.19M	0.2%	Form 4
Sep 3 – 4	Ugur Sahin Chief Executive Officer	Sold10b5-1 plan 2 parts	76,500	$103.13 average	$7.89M	8.9%	Form 4
Apr 22	Sierk Poetting Chief Operating Officer	Sold10b5-1 plan	50,000	$110.56	$5.53M	11%	Form 4

Oct 8 – 910b5-1 plan
Ugur Sahin
Chief Executive Officer · sold 63,209 at avg $94.07
$5.95M
0.2% of stake
Oct 710b5-1 plan
Ugur Sahin
Chief Executive Officer · sold 24,000 at $95.86
$2.3M
<0.1% of stake
Oct 5 – 610b5-1 plan
Ugur Sahin
Chief Executive Officer · sold 93,000 at avg $97.14
$9.03M
0.2% of stake
Oct 1 – 210b5-1 plan
Ugur Sahin
Chief Executive Officer · sold 34,000 at avg $97.09
$3.3M
<0.1% of stake
Sep 29 – 3010b5-1 plan
Ugur Sahin
Chief Executive Officer · sold 66,000 at avg $98.19
$6.48M
0.2% of stake
Sep 25 – 2810b5-1 plan
Ugur Sahin
Chief Executive Officer · sold 61,000 at avg $98.57
$6.01M
0.2% of stake
Sep 23 – 2410b5-1 plan
Ugur Sahin
Chief Executive Officer · sold 69,000 at avg $99.17
$6.84M
0.2% of stake
Sep 21 – 2210b5-1 plan
Ugur Sahin
Chief Executive Officer · sold 79,000 at avg $99.50
$7.86M
0.2% of stake
Sep 17 – 1810b5-1 plan
Ugur Sahin
Chief Executive Officer · sold 64,000 at avg $97.48
$6.24M
0.2% of stake
Sep 15 – 1610b5-1 plan
Ugur Sahin
Chief Executive Officer · sold 49,000 at avg $96.37
$4.72M
0.1% of stake
Sep 11 – 1410b5-1 plan
Ugur Sahin
Chief Executive Officer · sold 86,000 at avg $98.13
$8.44M
0.2% of stake
Sep 1010b5-1 plan
Ugur Sahin
Chief Executive Officer · sold 20,500 at $96.31
$1.97M
<0.1% of stake
Sep 8 – 910b5-1 plan
Ugur Sahin
Chief Executive Officer · sold 73,000 at avg $98.50
$7.19M
0.2% of stake
Sep 3 – 410b5-1 plan
Ugur Sahin
Chief Executive Officer · sold 76,500 at avg $103.13
$7.89M
8.9% of stake
Apr 2210b5-1 plan
Sierk Poetting
Chief Operating Officer · sold 50,000 at $110.56
$5.53M
11% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch BNTX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Biotechnology

REC.XMILRecordati Industria Chimica e Farmaceutica S.p.A.

GUBRA.XCSEGubra A/S

SECARE.XSTOSwedencare AB

STMN.XSWXStraumann

DYVOX.XSTODynavox Group AB

FIE.XETRFielmann Group AG

CTEC.XLONConvaTec

AMP.XMILAmplifon SpA

Spot a number that looks wrong?

Download this analysis as a PDF (Pro)

Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BNTX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.